Asia
Chinese Drug Regulator Accepts Sun-Novo Pharma's Application for Kidney Disease Drug's Clinical Trials
China's National Medical Products Administration accepted Beijing Sun-Novo Pharmaceutical Research's (SHA:688621) application for the clinical trials of STC009 injection, according to a Shanghai bourse filing on Saturday.The Chinese pharmaceutical company's shares rose less than 2% at the close of Monday's trade.The drug is being developed as a treatment for secondary hyperparathyroidism.
SHA:688621
